41.61
-0.07 (-0.17%)
| 前收盘价格 | 41.68 |
| 收盘价格 | 42.03 |
| 成交量 | 1,462,963 |
| 平均成交量 (3个月) | 2,373,240 |
| 市值 | 5,154,979,840 |
| 价格/销量 (P/S) | 7.81 |
| 股市价格/股市净资产 (P/B) | 55.67 |
| 52周波幅 | |
| 利润日期 | 5 Aug 2025 - 11 Aug 2025 |
| 营业毛利率 | -59.05% |
| 营业利益率 (TTM) | -62.79% |
| 稀释每股收益 (EPS TTM) | -3.56 |
| 季度收入增长率 (YOY) | 30.20% |
| 流动比率 (MRQ) | 4.68 |
| 营业现金流 (OCF TTM) | -239.86 M |
| 杠杆自由现金流 (LFCF TTM) | -146.83 M |
| 资产报酬率 (ROA TTM) | -16.95% |
| 股东权益报酬率 (ROE TTM) | -4,584.47% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 看跌 | 看跌 |
| Diagnostics & Research (全球的) | 看跌 | 看跌 | |
| 股票 | Guardant Health, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 3.0 |
| 内部交易活动 | -3.5 |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.30 |
|
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Growth |
| 内部持股比例 | 4.79% |
| 机构持股比例 | 98.66% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 70.00 (UBS, 68.23%) | 购买 |
| 中 | 60.00 (44.20%) | |
| 低 | 55.00 (Stephens & Co., 32.18%) | 购买 |
| 55.00 (Mizuho, 32.18%) | 购买 | |
| 平均值 | 60.22 (44.73%) | |
| 总计 | 9 购买 | |
| 平均价格@调整类型 | 46.37 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Piper Sandler | 06 May 2025 | 60.00 (44.20%) | 购买 | 41.93 |
| Scotiabank | 05 May 2025 | 57.00 (36.99%) | 购买 | 44.05 |
| Barclays | 01 May 2025 | 60.00 (44.20%) | 购买 | 48.87 |
| 10 Apr 2025 | 55.00 (32.18%) | 购买 | 41.14 | |
| Canaccord Genuity | 01 May 2025 | 65.00 (56.21%) | 购买 | 48.87 |
| Stifel | 01 May 2025 | 60.00 (44.20%) | 购买 | 48.87 |
| TD Securities | 01 May 2025 | 60.00 (44.20%) | 购买 | 48.87 |
| UBS | 01 May 2025 | 70.00 (68.23%) | 购买 | 48.87 |
| Mizuho | 10 Apr 2025 | 55.00 (32.18%) | 购买 | 41.14 |
| Stephens & Co. | 26 Mar 2025 | 55.00 (32.18%) | 购买 | 45.84 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| CHUDOVA DARYA | - | 40.62 | -161 | -6,540 |
| JOYCE MEGHAN V. | - | 42.10 | -100 | -4,210 |
| KALIA KUMUD | - | 43.21 | -4,254 | -193,477 |
| SAIA JOHN G. | - | 40.62 | -138 | -5,606 |
| TALASAZ AMIRALI | - | 48.67 | -119,284 | -5,847,821 |
| 累积净数量 | -123,937 | |||
| 累积净值 ($) | -6,057,654 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 44.47 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| TALASAZ AMIRALI | 职员 | 09 Jun 2025 | 自动卖出 (-) | 77,853 | 49.53 | 3,856,059 |
| TALASAZ AMIRALI | 职员 | 06 Jun 2025 | 自动卖出 (-) | 39,751 | 48.06 | 1,910,433 |
| TALASAZ AMIRALI | 职员 | 05 Jun 2025 | 自动卖出 (-) | 1,680 | 48.41 | 81,329 |
| JOYCE MEGHAN V. | 董事 | 04 Jun 2025 | 执行期权 | 67 | - | - |
| KALIA KUMUD | 职员 | 03 Jun 2025 | 卖 (-) | 4,000 | 45.79 | 183,160 |
| JOYCE MEGHAN V. | 董事 | 02 Jun 2025 | 卖 (-) | 100 | 42.10 | 4,210 |
| CHUDOVA DARYA | 职员 | 01 Jun 2025 | 处理 (-) | 161 | 40.62 | 6,540 |
| CHUDOVA DARYA | 职员 | 01 Jun 2025 | 执行期权 | 316 | - | - |
| KALIA KUMUD | 职员 | 01 Jun 2025 | 处理 (-) | 254 | 40.62 | 10,317 |
| KALIA KUMUD | 职员 | 01 Jun 2025 | 执行期权 | 710 | - | - |
| SAIA JOHN G. | 职员 | 01 Jun 2025 | 处理 (-) | 138 | 40.62 | 5,606 |
| SAIA JOHN G. | 职员 | 01 Jun 2025 | 执行期权 | 263 | - | - |
| 显示更多 | ||||||
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合